Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
g-csf mobilized hla-haploidentical donor peripheral blood stem cells
- Development stage
- Unknown
- Lead developer
- First Saint Petersburg State Medical University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
G-CSF mobilized HLA-haploidentical donor PBSC (peripheral blood stem cells) is an allogeneic cellular therapy being investigated by the First Saint Petersburg State Medical University for the treatment of acute myeloid leukemia (AML). The product consists of hematopoietic stem cells and lymphocytes collected from an HLA-haploidentical (half-matched) donor following mobilization with granulocyte colony-stimulating factor (G-CSF). Administered as an intravenous infusion, the therapy aims to induce a graft-versus-leukemia (GvL) effect, where the donor's immune cells recognize and eliminate residual leukemic cells in the recipient. In clinical research (NCT03381118), it is utilized as a consolidation therapy in older adults with AML in first or second remission, often in combination with cytarabine and the PD-1 inhibitor nivolumab to potentially enhance the anti-leukemic immune response.
- Other names
- G-CSF mobilized HLA-haploidentical donor PBSChaploidentical lymphocyte infusionhaploidentical donor PBSCG-CSF mobilized PBSC
Beyond the preview
Go deeper on g-csf mobilized hla-haploidentical donor peripheral blood stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on g-csf mobilized hla-haploidentical donor peripheral blood stem cells.